حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Zydus Lifesciences Limited
ZYDUSLIFEZydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust. Address: Zydus Corporate Park, Ahmedabad, India, 382481
Analytics
سعر الهدف في وول ستريت
91 374.16 INRنسبة السعر إلى الأرباح
22.2238العائد الربحي
0.32 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية ZYDUSLIFE
تحليلات الأرباح ZYDUSLIFE
نمو الأرباح على مدى 5 سنوات
71 %النمو المستمر
1 سنةمعدل الدفع 5 سنوات في المتوسط
21 %تاريخ الأرباح ZYDUSLIFE
تقييم الأسهم ZYDUSLIFE
المالية ZYDUSLIFE
نتائج | 2019 | ديناميات |